Nouscom Appoints Seasoned Government Eckhard Niemeier as Chief Enterprise Officer

BASEL, Switzerland – 3^rd December 2024 – Nouscom, a scientific stage immuno-oncology firm creating off-the-shelf and personalised neoantigen most cancers immunotherapies, publicizes the appointment of Eckhard Niemeier as its Chief Enterprise Officer (CBO). With over 20 years of expertise in life sciences company growth and technique, Eckhard will work carefully with the management workforce and play a key position in shaping Nouscom’s progress.

Dr. Marina Udier, CEO of Nouscom, commented on the appointment: “We’re delighted to welcome Eckhard to Nouscom. His confirmed observe file in forging collaborations with main pharmaceutical and biotech corporations aligns completely with our imaginative and prescient for progress and innovation. The following 12 months can be an thrilling time for Nouscom as we anticipate key information readouts from scientific trials with our lead asset, NOUS-209, in dMMR/MSI metastatic CRC and in Lynch Syndrome carriers. I stay up for working with Eckhard and the management workforce to form the subsequent section of progress for the corporate, leveraging each our pipeline alternatives, equivalent to NOUS-PEV, and the broad potential of our revolutionary platform.”

Eckhard joins Nouscom from UNION Therapeutics A/S, the place he served as CBO and was chargeable for all enterprise and company growth actions, together with in- and out-licensing, M&A, and alliance administration. His management was instrumental in advancing UNION’s portfolio and company technique. Beforehand, he held senior roles at Pieris Prescription drugs, the place he established strategic offers with main corporations together with AstraZeneca, Roche/Genentech, Seagen and Servier. Earlier than Pieris, Eckhard labored at Gruenenthal Pharma and MorphoSys, managing licensing and partnerships throughout all drug growth phases. He started his profession at McKinsey & Firm specializing in healthcare and life sciences. Eckhard holds a grasp’s diploma in biotechnology and accomplished his thesis at Human Genome Sciences.

Mr. Eckhard Niemeier, CBO, added: “I’m excited to affix Nouscom at such a key second. The corporate’s sturdy pipeline of off-the-shelf and personalised neoantigen most cancers immunotherapies, together with its revolutionary platform, current nice alternatives for exterior partnerships. I stay up for working with the workforce to unlock worth and ship doubtlessly significant most cancers therapies to sufferers.”

Ends

About Nouscom

Nouscom is a clinical-stage immuno-oncology firm creating next-generation, off-the-shelf and personalised most cancers immunotherapies. Nouscom’s proprietary viral vector platform has the capability to encode for giant payloads of neoantigens or different immunomodulators and clinically demonstrated to securely and potently harness the ability of the immune system.

Nouscom is presently advancing the scientific growth of its wholly owned applications:

• NOUS-209, an off-the-shelf neoantigen most cancers immunotherapy, for the remedy of MSI strong tumors together with pembrolizumab in a randomized Section 2 trial. 

• NOUS-209 monotherapy in Lynch Syndrome carriers with the potential to ‘intercept most cancers’ earlier than it advances. A Section 1b/2 is being performed underneath a Medical Trial Collaboration and Provide Settlement with the Nationwide Most cancers Institute (NCI).

• NOUS-PEV, a customized most cancers immunotherapy, is predicted to enter randomized Section 2 trials in indications with excessive unmet medical want throughout 2025.

Nouscom has additionally solely out-licensed VAC-85135, an off-the-shelf immunotherapy developed underneath a multi-project settlement, which is presently underneath analysis in a Section 1 trial for the remedy of Myeloproliferative Neoplasms sponsored by Janssen Analysis & Growth and Bristol Myers Squibb.

For extra data on Nouscom, please go to the corporate’s web site at www.nouscom.com or observe us on LinkedIn.

Contacts